Fortress Biotech (FBIO) News Today $2.25 -0.35 (-13.46%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 25 at 8:30 AM | globenewswire.comFortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027July 25 at 7:30 AM | globenewswire.comCheckpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell CarcinomaJuly 24 at 2:06 AM | americanbankingnews.comFortress Biotech (NASDAQ:FBIO) Cut to "Sell" at StockNews.comJuly 20, 2024 | americanbankingnews.comFortress Biotech (NASDAQ:FBIO) Receives "Buy" Rating from HC WainwrightJuly 19, 2024 | markets.businessinsider.comFortress Biotech’s Strategic Financial Moves and Clinical Pipeline Promise Bright Revenue Prospects: Pantginis Issues Buy RatingJuly 18, 2024 | americanbankingnews.comStockNews.com Upgrades Fortress Biotech (NASDAQ:FBIO) to "Hold"July 16, 2024 | insidertrades.comLindsay A. Md Rosenwald Acquires 5,000 Shares of Fortress Biotech, Inc. (NASDAQ:FBIO) StockJuly 15, 2024 | globenewswire.comGC Cell and Checkpoint Therapeutics Advance Collaborative Cancer ResearchJuly 11, 2024 | globenewswire.comJourney Medical Corporation Appoints Michael C. Pearce to Board of DirectorsJuly 5, 2024 | globenewswire.comFortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred StockJuly 2, 2024 | globenewswire.comCheckpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJuly 2, 2024 | globenewswire.comCheckpoint Therapeutics Announces Biologics License Application Resubmission for CosibelimabJuly 2, 2024 | insidertrades.comLindsay A. Md Rosenwald Buys 20,000 Shares of Fortress Biotech, Inc. (NASDAQ:FBIO) StockJune 24, 2024 | globenewswire.comCheckpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA ResubmissionMay 21, 2024 | insidertrades.comInsider Buying: Fortress Biotech, Inc. (NASDAQ:FBIO) CEO Buys 10,000 Shares of StockMay 16, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Fortress Biotech (FBIO), BioLife Solutions (BLFS)May 16, 2024 | finanznachrichten.deFortress Biotech, Inc.: Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsMay 16, 2024 | finance.yahoo.comFortress Biotech to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company ShowcaseMay 16, 2024 | finance.yahoo.comAvenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)May 16, 2024 | globenewswire.comFortress Biotech to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company ShowcaseMay 15, 2024 | globenewswire.comFortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsMay 15, 2024 | globenewswire.comJourney Medical Corporation to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company ShowcaseMay 14, 2024 | globenewswire.comFortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver TransplantationMay 13, 2024 | globenewswire.comJourney Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsMay 13, 2024 | globenewswire.comCheckpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceMay 10, 2024 | globenewswire.comCheckpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate UpdatesMay 7, 2024 | globenewswire.comJourney Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024May 1, 2024 | globenewswire.comJourney Medical Corporation Appoints Joseph Benesch as Chief Financial OfficerApril 25, 2024 | globenewswire.comJourney Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024April 11, 2024 | investorplace.com3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024March 29, 2024 | finanznachrichten.deFortress Biotech, Inc.: Fortress Biotech Reports 2023 Financial Results and Recent Corporate HighlightsMarch 28, 2024 | globenewswire.comFortress Biotech Reports 2023 Financial Results and Recent Corporate HighlightsMarch 28, 2024 | finanznachrichten.deMustang Bio, Inc.: Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune DiseasesMarch 28, 2024 | msn.comMustang Bio stock climbs 9% amid drug development updateMarch 22, 2024 | globenewswire.comCheckpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsMarch 21, 2024 | globenewswire.comJourney Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsMarch 18, 2024 | finance.yahoo.comAvenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate HighlightsMarch 18, 2024 | globenewswire.comJourney Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of RosaceaMarch 15, 2024 | globenewswire.comJourney Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024March 13, 2024 | globenewswire.comJourney Medical Corporation to Participate in the 36th Annual ROTH ConferenceMarch 12, 2024 | globenewswire.comFortress Biotech to Participate in 36th Annual ROTH ConferenceMarch 11, 2024 | globenewswire.comJourney Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual MeetingMarch 4, 2024 | globenewswire.comFortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes DiseaseJanuary 29, 2024 | finance.yahoo.comCheckpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-MarketJanuary 11, 2024 | finance.yahoo.comAvenue Therapeutics to Present at Sidoti January Micro-Cap Investor ConferenceJanuary 9, 2024 | finance.yahoo.comInsider Buying: President, CEO & Chairman, 10% Owner ROSENWALD LINDSAY A MD Acquires 50,000 ...January 5, 2024 | finance.yahoo.comJourney Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat RosaceaJanuary 5, 2024 | finance.yahoo.comAvenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in ProceedsJanuary 4, 2024 | finance.yahoo.comAvenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV TramadolJanuary 2, 2024 | finance.yahoo.comAvenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) Get Fortress Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address J.P. Morgan’s DIRE Warning (Ad)When the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell." Click here to see why Wall Street is in PANIC mode >>> FBIO Media Mentions By Week FBIO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FBIO News Sentiment▼0.380.61▲Average Medical News Sentiment FBIO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FBIO Articles This Week▼61▲FBIO Articles Average Week Get Fortress Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CMRX News SCPH News RIGL News ACHV News AGEN News RGLS News VSTM News SGMO News CRIS News BOLT News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FBIO) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fortress Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fortress Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
